BlackRock
UNCY icon

BlackRock’s Unicycive Therapeutics UNCY Stock Holding History

BlackRock’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.63M Buy
1,413,381
+1,377,478
+3,837% +$10.2M ﹤0.01% 3841
2026
Q1 		$236K Sell
35,903
-452
-1% -$2.96K ﹤0.01% 4723
2025
Q4 		$210K Hold
36,355
– – ﹤0.01% 4712
2025
Q3 		$159K Buy
+36,355
New +$158K ﹤0.01% 4729
2025
Q2 		– Sell
-8,324
Closed -$47.9K – 5591
2025
Q1 		$47.9K Buy
8,324
+1,097
+15% +$6.69K ﹤0.01% 4927
2024
Q4 		$57.4K Buy
7,227
+45
+0.6% +$249 ﹤0.01% 4911
2024
Q3 		$29.3K Buy
7,182
+1,998
+39% +$8.02K ﹤0.01% 4894
2024
Q2 		$26K Buy
+5,184
New +$51K ﹤0.01% 4970
2022
Q2 		– Sell
-2,417
Closed -$31K – 5990
2022
Q1 		$31K Buy
2,417
+812
+51% +$11.9K ﹤0.01% 5503
2021
Q4 		$33K Buy
1,605
+461
+40% +$11.5K ﹤0.01% 5475
2021
Q3 		$33K Buy
+1,144
New +$32.8K ﹤0.01% 5343

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

BlackRock's UNCY Position: Q2 2026 in Review

BlackRock increased its Unicycive Therapeutics (UNCY) stake by 3,837% in Q2 2026, buying an estimated $10.2M and bringing the position to 1,413,381 shares worth $6.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3841.

BlackRock first reported a position in UNCY in Q3 2021 and has held it in 11 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • BlackRock held 1,413,381 shares of Unicycive Therapeutics worth $6.63M as of Q2 2026.
  • BlackRock bought 1,377,478 Unicycive Therapeutics shares in Q2 2026, an estimated $10.2M.
  • Unicycive Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3841 holding.
  • BlackRock first reported a position in Unicycive Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.